Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban

Argatroban is licensed for patients with heparin‐induced thrombocytopenia and monitoring is conventionally by activated partial thromboplastin time (APTT) ratio with a target of 1.5–3.0 and not exceeding 100 s. The APTT may be influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. Variable but not clinically significant sensitivity of APTT reagents to argatroban has been highlighted in other studies.

[1]  T. Trujillo,et al.  Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. , 2014, American journal of clinical pathology.

[2]  C. Alaniz,et al.  Apparent Argatroban Resistance in a Patient with Elevated Factor VIII Levels , 2013, The Annals of pharmacotherapy.

[3]  W. Chandler,et al.  Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time , 2013, The Annals of pharmacotherapy.

[4]  H. Watson,et al.  Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition , 2012, British journal of haematology.

[5]  D. van de Kerkhof,et al.  Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? , 2012, American journal of clinical pathology.

[6]  A. Koster,et al.  Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. , 2012, Thrombosis research.

[7]  Michael P Gulseth,et al.  High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  A. Dans,et al.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[9]  D. Zakalik,et al.  Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit “overdiagnosis” in a patient with antiphospholipid syndrome , 2011, American journal of hematology.

[10]  C. Samama,et al.  Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: a case report. , 2010, Thrombosis research.

[11]  W. Chandler,et al.  Monitoring direct thrombin inhibitors with a plasma diluted thrombin time , 2007, Thrombosis and Haemostasis.

[12]  Jörg Ingrid,et al.  Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban , 2005, Journal of Thrombosis and Thrombolysis.

[13]  J. Harenberg,et al.  Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  J. Francis,et al.  Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  J. T. Owings,et al.  Comparing Direct Thrombin Inhibitors Using aPTT, Ecarin Clotting Times, and Thrombin Inhibitor Management Testing , 2004, The Annals of pharmacotherapy.

[16]  J. Kelton,et al.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. , 2003, Archives of internal medicine.

[17]  J. Harenberg,et al.  Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors , 2002, Seminars in thrombosis and hemostasis.

[18]  S. Swan,et al.  Comparison of Anticoagulant Effects and Safety of Argatroban and Heparin in Healthy Subjects , 2000, Pharmacotherapy.

[19]  D. Hoppensteadt,et al.  Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients , 1998 .

[20]  G. Wolf,et al.  Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. , 2008, Thrombosis research.